FDA approves GlaxoSmithKline’s Votrient™ for advanced renal cell cancer
Media
GSK announced that FDA has approved Votrient to treat patients with advanced renal cell carcinoma (RCC).
https://www.gsk.com/en-gb/media/press-releases/fda-approves-glaxosmithkline-s-votrient-for-advanced-renal-cell-cancer/
First published: 19 October 2009
